IPOs & Offerings

iSpecimen Prospectus Details Best-Efforts Common Stock and Pre-Funded Warrant Offering

iSpecimen Inc.’s prospectus describes a best-efforts offering of common stock priced at $1.30 per share, with pre-funded warrants available in place of shares for certain purchasers subject to ownership limits.

By Carter Hayes ·

Key takeaways

  • The prospectus covers 996,231 common shares, pre-funded warrants to purchase up to 2,849,922 common shares, and the shares issuable upon exercise of those warrants.
  • For each pre-funded warrant sold, the number of common shares offered is reduced on a one-for-one basis.
  • The offering has no minimum closing amount, so the actual offering amount, placement-agent fee and proceeds were not determinable when the prospectus was filed.
  • E.F. Hutton & Co. is the exclusive placement agent and is not required to arrange sales of a specified number of securities or dollar amount.

Offering terms and structure

iSpecimen filed a prospectus for a best-efforts offering of 996,231 shares of common stock at a public offering price of $1.30 per share. The prospectus also registers pre-funded warrants to purchase up to 2,849,922 shares of common stock, along with the shares that may be issued upon exercise of those warrants.

The company is offering pre-funded warrants to purchasers whose beneficial ownership would otherwise exceed 4.99% of outstanding common stock immediately after the offering. Each pre-funded warrant is exercisable for one common share. For every pre-funded warrant sold, the number of common shares offered is reduced by one share.

The pre-funded warrant purchase price is the common-share price less $0.0001, and the remaining exercise price is $0.0001 per share. The warrants are immediately exercisable, subject to the beneficial-ownership cap, and may be exercised until they have been exercised in full.

Ownership limits and trading status

A warrant holder generally may not exercise warrants if the holder and its affiliates would beneficially own more than 4.99% of the company’s outstanding common stock after the exercise. A holder may elect to raise that limit to as much as 9.99% by providing at least 61 days’ prior notice to iSpecimen.

iSpecimen’s common stock is listed on the Nasdaq Capital Market under the symbol ISPC. The prospectus reported a closing price of $1.92 per share on August 5, 2026.

The company said there is no established public market for the pre-funded warrants and that it does not intend to seek their listing on a securities exchange or recognized trading system.

Closing conditions and placement arrangement

The securities were expected to be issued in a single closing, with the offering expected to be completed on or about August 7, 2026. The prospectus presents this as an expectation and does not confirm completion of the offering or the amount sold.

The offering has no minimum amount required as a closing condition. iSpecimen said the actual public offering amount, placement-agent fee and proceeds, if any, were not then determinable and could be substantially below the maximum amounts shown in the prospectus.

E.F. Hutton & Co. was engaged as exclusive placement agent to use reasonable best efforts to solicit purchase offers. The placement agent is not purchasing or selling the securities and is not required to arrange a particular number of sales or a particular dollar amount. The company also stated that neither it nor the placement agent had arranged an escrow or trust account for investor funds.